Yin Shan Eric Ng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4780749/publications.pdf

Version: 2024-02-01

41 papers

4,545 citations

279798 23 h-index 330143 37 g-index

42 all docs 42 docs citations

times ranked

42

5036 citing authors

#	Article	IF	CITATIONS
1	Discovery of sterically-hindered phenol compounds with potent cytoprotective activities against ox-LDL–induced retinal pigment epithelial cell death as a potential pharmacotherapy. Free Radical Biology and Medicine, 2022, 178, 360-368.	2.9	3
2	Galectin-3 Enhances Vascular Endothelial Growth Factor-A Receptor 2 Activity in the Presence of Vascular Endothelial Growth Factor. Frontiers in Cell and Developmental Biology, 2021, 9, 734346.	3.7	7
3	Novel engineered, membraneâ€ŧethered VEGFâ€A variants promote formation of filopodia, proliferation, survival, and cord or tube formation by endothelial cells via persistent VEGFR2/ERK signaling and activation of CDC42/ROCK pathways. FASEB Journal, 2021, 35, e22036.	0.5	5
4	Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization. Cells, 2020, 9, 2057.	4.1	14
5	Elements of the Endomucin Extracellular Domain Essential for VEGF-Induced VEGFR2 Activity. Cells, 2020, 9, 1413.	4.1	11
6	ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. Journal of Biological Chemistry, 2020, 295, 6641-6651.	3.4	15
7	Glycocalyx regulation of vascular endothelial growth factor receptor 2 activity. FASEB Journal, 2019, 33, 9362-9373.	0.5	19
8	Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study. Cell Death and Disease, 2018, 9, 1018.	6.3	12
9	A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. American Journal of Pathology, 2017, 187, 2208-2221.	3.8	27
10	Endomucin inhibits VEGF-induced endothelial cell migration, growth, and morphogenesis by modulating VEGFR2 signaling. Scientific Reports, 2017, 7, 17138.	3.3	59
11	Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism. Cell Death and Disease, 2016, 7, e2212-e2212.	6.3	25
12	Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres. Journal of Visualized Experiments, 2015, , .	0.3	17
13	Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability. American Journal of Pathology, 2015, 185, 2534-2549.	3.8	24
14	Endomucin Plays a Role in Retinal Vascular Development and in VEGFâ€Induced Endothelial Cell Migration, Growth, and Morphogenesis. FASEB Journal, 2015, 29, 418.1.	0.5	1
15	Spontaneous CNV in a Novel Mutant Mouse Is Associated With Early VEGF-A–Driven Angiogenesis and Late-Stage Focal Edema, Neural Cell Loss, and Dysfunction. , 2014, 55, 3709.		43
16	VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma. American Journal of Pathology, 2013, 182, 1379-1390.	3.8	151
17	Assessing a Novel Depot Delivery Strategy for Noninvasive Administration of VEGF/PDGF RTK Inhibitors for Ocular Neovascular Disease., 2013, 54, 1490.		49
18	Systemic Administration of Abeta mAb Reduces Retinal Deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model. PLoS ONE, 2013, 8, e65518.	2.5	27

#	Article	IF	CITATIONS
19	Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular injury in a porcine model. Journal of Vascular Surgery, 2012, 56, 1078-1088.	1.1	11
20	Delivery Site of Perivascular Endothelial Cell Matrices Determines Control of Stenosis in a Porcine Femoral Stent Model. Journal of Vascular and Interventional Radiology, 2009, 20, 1617-1624.	0.5	14
21	The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure–function study. Biochemical Society Transactions, 2009, 37, 1201-1206.	3.4	63
22	RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis, 2008, 11, 141-151.	7.2	80
23	The Biology of Vascular Endothelial Cell Growth Factor Isoforms. , 2008, , 1-13.		4
24	Molecular Mapping and Functional Characterization of the VEGF164 Heparin-binding Domain. Journal of Biological Chemistry, 2007, 282, 28045-28056.	3.4	82
25	Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice., 2007, 48, 1212.		139
26	Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury. American Journal of Pathology, 2007, 171, 53-67.	3.8	636
27	VEGF function in vascular pathogenesis. Experimental Cell Research, 2006, 312, 527-537.	2.6	114
28	An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16770-16775.	7.1	79
29	A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18902-18907.	7.1	212
30	Identification of genes involved in VEGF-mediated vascular morphogenesis using embryonic stem cell-derived cystic embryoid bodies. Laboratory Investigation, 2004, 84, 1209-1218.	3.7	48
31	VEGF expression is downregulated in nitrofen-induced congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2004, 39, 825-828.	1.6	55
32	VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization. Journal of Experimental Medicine, 2003, 198, 483-489.	8.5	413
33	Defective Pulmonary Development in the Absence of Heparin-Binding Vascular Endothelial Growth Factor Isoforms. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 194-203.	2.9	148
34	Won't You Be My Neighbor? Local Induction of Arteriogenesis. Cell, 2002, 110, 289-292.	28.9	42
35	Tales of the cryptic: unveiling more angiogenesis inhibitors. Trends in Molecular Medicine, 2002, 8, 313-315.	6.7	14
36	Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. Journal of Clinical Investigation, 2002, 109, 327-336.	8.2	340

#	Article	IF	CITATIONS
37	Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. Journal of Clinical Investigation, 2002, 109, 327-336.	8.2	229
38	Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis. Development (Cambridge), 2002, 129, 1893-1904.	2.5	387
39	Therapeutic angiogenesis for cardiovascular disease. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 278.	1.5	38
40	Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Medicine, 1999, 5, 495-502.	30.7	618
41	The Mouse Gene for Vascular Endothelial Growth Factor. Journal of Biological Chemistry, 1996, 271, 3877-3883.	3.4	270